|Study Description:||The goal of this clinical research study is to learn the highest tolerable dose |
of ARRY-614 that can be given to patients with MDS either 1 or 2 times a day.
ARRY-614 is designed to block the function of certain proteins that cause
normal blood cells to die in patients with MDS. This could cause the normal
blood cells to survive.